Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024)
Avalo Therapeutics posted quarterly Preferred Stock Liabilities of $1.7 million for Q3 2024, down 85.53% on a QoQ basis from $11.5 million in Q2 2024.
Avalo Therapeutics (AVTX) has 3 years of Preferred Stock Liabilities data on file, last reported at $1.7 million in Q3 2024.
- For the quarter ending Q3 2024, Preferred Stock Liabilities changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Sep 2024 stood at $1.7 million (changed N/A YoY), and the FY2014 full-year result was $28.3 million, up 42.75% from the prior year.
- Preferred Stock Liabilities for Q3 2024 stood at $1.7 million, down from $11.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $11.5 million in Q1 2024 and bottomed at $1.7 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 11.46 Mn |
| Mar 31, 2024 | 11.46 Mn |
| Sep 30, 2015 | 28.35 Mn |
| Dec 31, 2014 | 28.35 Mn |